Is Extending the Gilead E3 Ligase Collaboration Altering The Investment Case For Nurix Therapeutics (NRIX)?

Nurix Therapeutics, Inc. recently announced that it has extended by two years the research term for an undisclosed oncology program under its ongoing collaboration with Gilead Sciences, originally established in 2019 to develop E3 ligase–based protein degradation therapies. This extension underscores continued progress in a partnership that could earn Nurix up to approximately US$1.30 billion in potential payments, plus tiered royalties on any future commercial products, with options for...